Zhejiang Medicine Co., Ltd. (SHA: 600216)
China
· Delayed Price · Currency is CNY 16.75
+0.11 (0.66%)
Nov 19, 2024, 3:00 PM CST
Zhejiang Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 977.95 | 429.64 | 539.57 | 1,045 | 717.4 | 342.77 | Upgrade
|
| Depreciation & Amortization | 659.38 | 659.38 | 681.6 | 587.57 | 503.81 | 487.74 | Upgrade
|
| Other Amortization | 68.24 | 68.24 | 3.75 | 0.08 | 1.12 | 0.95 | Upgrade
|
| Loss (Gain) From Sale of Assets | -330.16 | -330.16 | -3.31 | 7.95 | 23.48 | -0.1 | Upgrade
|
| Asset Writedown & Restructuring Costs | 15.81 | 15.81 | 12.8 | 46.19 | 9.85 | 9.11 | Upgrade
|
| Loss (Gain) From Sale of Investments | 28.59 | 28.59 | 56.51 | -93.54 | -150.22 | -101.4 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.15 | 0.15 | -2.94 | 10.63 | -16.47 | 12.66 | Upgrade
|
| Other Operating Activities | -343.37 | -76.42 | -73.46 | 58.32 | 173.37 | 56.12 | Upgrade
|
| Change in Accounts Receivable | -29.42 | -29.42 | -161.98 | -402.19 | 76.5 | -172.79 | Upgrade
|
| Change in Inventory | -263.73 | -263.73 | -330.7 | -760.57 | -215.11 | -414.77 | Upgrade
|
| Change in Accounts Payable | 101.7 | 101.7 | -218.05 | 577.5 | 154.68 | 230.62 | Upgrade
|
| Change in Other Net Operating Assets | 37.47 | 37.47 | 33.35 | 42.24 | - | - | Upgrade
|
| Operating Cash Flow | 915.67 | 634.31 | 520.6 | 1,137 | 1,257 | 447.25 | Upgrade
|
| Operating Cash Flow Growth | 15.89% | 21.84% | -54.20% | -9.55% | 180.99% | -22.88% | Upgrade
|
| Capital Expenditures | -632.71 | -796.87 | -975.99 | -939.6 | -535.35 | -573.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 192.37 | 174.48 | 7.2 | 6.97 | 27.43 | 2.42 | Upgrade
|
| Cash Acquisitions | - | - | - | -140.73 | - | - | Upgrade
|
| Divestitures | - | - | 9.12 | - | -1.6 | -0.01 | Upgrade
|
| Investment in Securities | 91.55 | 102.02 | -40.46 | 39.13 | 300.32 | -56.77 | Upgrade
|
| Other Investing Activities | -74.56 | 0.78 | 1.75 | 1.98 | 6.64 | 2.63 | Upgrade
|
| Investing Cash Flow | -422.34 | -518.59 | -971.15 | -983.69 | -237.72 | -618.19 | Upgrade
|
| Long-Term Debt Issued | - | 600 | 660.74 | 580 | 1,400 | 697.96 | Upgrade
|
| Long-Term Debt Repaid | - | -600.34 | -726.21 | -700.43 | -1,098 | -545.09 | Upgrade
|
| Net Debt Issued (Repaid) | -52.34 | -0.34 | -65.47 | -120.43 | 302.04 | 152.87 | Upgrade
|
| Issuance of Common Stock | - | - | 59.95 | - | - | - | Upgrade
|
| Repurchase of Common Stock | -1.29 | -1.29 | - | - | - | -39.54 | Upgrade
|
| Common Dividends Paid | -170.94 | -191.91 | -351.09 | -260.06 | -1,006 | -168 | Upgrade
|
| Other Financing Activities | -30.51 | 52.12 | 400.53 | 450.25 | 76.73 | -7.94 | Upgrade
|
| Financing Cash Flow | -255.09 | -141.43 | 43.91 | 69.75 | -627.47 | -62.6 | Upgrade
|
| Foreign Exchange Rate Adjustments | 47.74 | 47.64 | 76.01 | -79.84 | -42.7 | 19.53 | Upgrade
|
| Net Cash Flow | 285.98 | 21.93 | -330.62 | 142.88 | 348.82 | -214.02 | Upgrade
|
| Free Cash Flow | 282.96 | -162.56 | -455.39 | 197.05 | 721.37 | -126.38 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -72.68% | - | - | Upgrade
|
| Free Cash Flow Margin | 3.13% | -2.09% | -5.61% | 2.16% | 9.85% | -1.79% | Upgrade
|
| Free Cash Flow Per Share | 0.30 | -0.17 | -0.47 | 0.21 | 0.75 | -0.13 | Upgrade
|
| Cash Interest Paid | 0.4 | 0.4 | 0.4 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 256.55 | 163.05 | 344.56 | 384.41 | 307.7 | 316.59 | Upgrade
|
| Levered Free Cash Flow | 312.59 | -60.17 | -899.57 | 1,076 | 613.73 | -233.6 | Upgrade
|
| Unlevered Free Cash Flow | 330.4 | -42.46 | -878.88 | 1,100 | 642.65 | -217.53 | Upgrade
|
| Change in Net Working Capital | 257.61 | -0.67 | 927.62 | -684.91 | -185.99 | 306.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.